A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Inclusion Criteria: * Subject's written informed consent obtained prior to any process, sampling, or analysis related to the study. * Male or female, no less than 18 years old. * Confirmed as NSCLC by histology or cytology. * Locally advanced or metastatic NSCLC and not suitable for radical surgery or radiotherapy. * Have not received EGFR Tyrosine Kinase Inhibitor (TKI) therapy. * At least one baseline tumor lesion. * Can swallow pills normally. * Eastern Cooperative Oncology Group (ECOG) performance status 0\~1 points, expected survival≥12 weeks. * Adequate organ function. Exclusion Criteria: * Clinically symptomatic central nervous system metastases. * Ascites, pleural effusion or pericardial effusion with clinical symptoms. * Other malignant tumors in the past 5 years or at the same time. * High blood pressure which are not well controlled. * Heart disease that are not well controlled. * Coagulation dysfunction, bleeding tendency or receiving thrombolysis or anticoagulant therapy. * History of bleeding. * Known hereditary or acquired bleeding and thrombophilia. * Any serious or uncontrolled ocular lesion. * Interstitial lung disease or non-infectious pneumonia treated with corticosteroids. * Congenital or acquired immunodeficiency. * Other factors that may affect the results of the study or cause the study to be terminated midway.